SHARPIN and glioblastoma: Firstly, we performed a Kaplan–Meier estimator survival analysis with 220 cases of glioblastoma (IDH WT and mutated); of these cases, 109 had high expression of SHARPIN, and 111 had low expression of the marker (Figure 3c).